Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer (Q33389302)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer |
scientific article |
Statements
1 reference
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer (English)
1 reference
Shanu Modi
1 reference
Ian E Krop
1 reference
Muralidhar Beeram
1 reference
Suzanne F Jones
1 reference
Scott N Holden
1 reference
Wei Yu
1 reference
Sandhya Girish
1 reference
Jay Tibbitts
1 reference
Joo-Hee Yi
1 reference
Mark X Sliwkowski
1 reference
Fred Jacobson
1 reference
Stuart G Lutzker
1 reference
Howard A Burris
1 reference
1 reference
Identifiers
1 reference